Susan Dent MD FRCPC

It is so important to understand how cancer treatments impact cardiovascular health!

Best of luck in your new adventures. You have made such significant contribution’s to cancer care and I know you will continue to do so……

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer - Apr 17, 2025
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...

Cardio-Oncology Screening Program Ensures Timely Referrals for Cardiotoxicity  - Oncology Nurse Advisor Screening program provides timely referrals to patients with cancer for management of potential cardiotoxicities.

Cardio-Oncology screening program ensures timely referrals for cardiotoxicity #oncologynursing #ONS50 #ONSCongress
www.oncologynurseadvisor.com/reports/canc...

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...

In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42

Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social

ascopubs.org/doi/10.1200/...

Radionecrosis After Dual Immune-Checkpoint Inhibition for Brain Metastases This cohort study evaluates whether immune-checkpoint inhibition therapy concurrent with radiosurgery is associated with risk of symptomatic radionecrosis among US patients with brain metastases.

jamanetwork.com/journals/jam...

Congratulations to the University of Rochester for being named the 73rd NCI designated Cancer Center!!!!

Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...

On International Women’s Day spending time with this amazing group of women who provide flying fishing retreats for breast cancer survivors!

I missed this poll but this is a bit scary!!! 8 % said Ribociclib which is absolutely contraindicated and honestly I would be hesitant to start her on any cdk4/6 inhibitor with a QTc that high particularly given she is on seroquel. Speed dial to cardio-oncology! Education needed!

Important to consider comorbidities when selecting first line therapy in HR+HER2- metastatic breast cancer !

Dear colleagues. We have an exciting opportunity for a breast cancer medical oncologist in Rochester New York! If you are interested in leading a dynamic clinical research program let me know. Come and join a growing team while enjoying the wonderful nature of upper state New York!

The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changi...

Interesting endpoint and trial.

Few MBC patients treated and very small.

For oligoprogressive cancer,
SBRT could delay time to systemic therapy change.

This could could valuable for the right patient trying to delay time to chemotherapy.

www.redjournal.org/article/S036...

🆕
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social

thelancet.com/journals/lanon…

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109) Concomitant intake of proton pump inhibitors (PPIs) may create drug–drug interactions, potentially impacting efficacy of anticancer agents. In the pha…

What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻

@oncoalert.bsky.social
www.sciencedirect.com/science/arti...

Happy new year to all

Cure Cancer Save Hearts!

Sorry Save Hearts

IC-OS 2024 Newsletter

77510762.flowpaper.com/ICOS2024News...
Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!

Title: Insurance profits outpace health care spending Subtitle: Increase in combined earnings of UnitedHealth Group, Evelance, and Cigna Photo: A line graph that shows the increase in combined earnings of UnitedHealth Group, Elevance, and Cigna (shown as "Cumulative earnings") compared to the increase in national health care expenditures over time from 2012 to 2022. “Cumulative earnings” moves from 8.35% in 2012 to 261.56% in 2022. “National” moves from 4% in 2012 to 67% in 2022. Chart credit: Michael Mechanic/Mother Jones. Source: Commonwealth Fund

3. Insurance profits outpace health care spending

Survivorship means different things to different individuals. One of which remains how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines to ensure equitable & comprehensive care #oncsky #oncologynursing
jnccn.org/view/journal...

📣Abstract deadline for St. Gallen’s Breast Cancer Consensus Conf extended!! The top 5️⃣ posters present in front of global leaders. 🌍 [plus you’ll join me in beautiful Vienna 🇦🇹]

Final deadline: Jan 5, 2025
🔗 sgbcc2025.abstractserver.com/submission/#...
#oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social

Bravo Kate! Thank you for your leadership and commitment to children everywhere.

Overview of #SABCS24! So many important trials presented. @oncoalert.bsky.social #breastcancer

Prostate Cancer Therapy Cardiotoxicity Map:
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social

Congrats!

Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ

Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial…

www.sciencedirect.com/science/arti...
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!